Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: An international prospective breast cancer family registry population-based cohort study

Journal of Clinical Oncology

Volumn 30, Issue 1, 2012, Pages 19-26

  Goodwin, Pamela J ^a,b,c   Phillips, Kelly Anne ^g,h,i   West, Dee W ^m   Ennis, Marguerite ^f   Hopper, John L ⁱ   John, Esther M ^l,m   O'Malley, Frances P ^c,d   Milne, Roger L ^i,n   Andrulis, Irene L ^b,c,e   Friedlander, Michael L ^k   Southey, Melissa C ⁱ   Apicella, Carmel ⁱ   Giles, Graham G ^j   Longacre, Teri A ^m  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e CANCER CARE ONTARIO   (Canada)

^f Applied Biostatistics   (Canada)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j CANCER EPIDEMIOLOGY CENTRE   (Australia)

^k PRINCE OF WALES HOSPITAL   (Australia)

^l CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ Centro Nacional de Investigaciones Oncológicas   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR;

ADULT; ARTICLE; AUSTRALIA; BREAST CANCER; CANADA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; AUSTRALIA; BREAST NEOPLASMS; CANADA; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; INTERNATIONAL COOPERATION; JEWS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; UNITED STATES;

EID: 84855521780     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.0068     Document Type: Article

References (41)

1. Bordeleau L, Panchal S, Goodwin PJ: Prognosis of BRCA related breast cancer: A summary of evidence. Breast Cancer Res Treat 119:13-24, 2010
2. Phillips KA, Nichol K, Ozcelik H, et al: Frequency of p53 mutations in breast carcinomas of Ashkenazi Jewish BRCA1 mutation carriers. J Natl Cancer Inst 91:469-473, 1999 (Pubitemid 29128285)
3. Phillips KA: Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18:107S-112S, 2000 (suppl)
4. Quenneville LA, Phillips KA, Ozcelik H, et al: HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer 95:2068-2075, 2002 (Pubitemid 35253367)
5. Bane AL, Beck JC, Bleiweiss I, et al: BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 31:121-128, 2007 (Pubitemid 46036911)
6. Honrado E, Benítez J, Palacios J: The molecular pathology of hereditary breast cancer: Genetic testing and therapeutic implications. Mod Pathol 18:1305-1320, 2005 (Pubitemid 41348649)
7. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819, 2004 (Pubitemid 39331153)
8. Rubinstein WS: Hereditary breast cancer: Pathobiology, clinical translation, and potential for targeted cancer therapeutics. Fam Cancer 7:83-89, 2008
9. Porter DE, Cohen BB, Wallace MR, et al: Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 81:1512-1515, 1994 (Pubitemid 24306008)
10. Marcus JN, Watson P, Page DL, et al: Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709, 1996 (Pubitemid 26055395)
11. Gaffney DK, Brohet RM, Lewis CM, et al: Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 47:129-136, 1998 (Pubitemid 28275921)
12. Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351:316-321, 1998 (Pubitemid 28052696)
13. Phillips KA, Andrulis IL, Goodwin PJ: Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different? J Clin Oncol 17:3653-3663, 1999 (Pubitemid 29517937)
14. Foulkes WD, Wong N, Brunet JS, et al: Germline BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3:2465-2469, 1997 (Pubitemid 28133169)
15. Robson M, Gilewski T, Haas B, et al: BRCA-associated breast cancer in young women. J Clin Oncol 16:1642-1649, 1998
16. Johannsson OT, Ranstam J, Borg A, et al: Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 16:397-404, 1998 (Pubitemid 28135579)
17. Robson M, Levin D, Federici M, et al: Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112-2117, 1999 (Pubitemid 30019573)
18. Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17:3396-3402, 1999 (Pubitemid 29517906)
19. Foulkes WD, Chappuis PO, Wong N, et al: Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 11:307-313, 2000 (Pubitemid 30214668)
20. Chappuis PO, Kapusta L, Bégin LR, et al: Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 18:4045-4052, 2000 (Pubitemid 32038396)
21. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al: Familial invasive breast cancers: Worse outcome related to BRCA1 mutations. J Clin Oncol 18:4053-4059, 2000 (Pubitemid 32038397)
22. Loman N, Johannsson O, Bendahl P, et al: Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer 36:1365-1373, 2000 (Pubitemid 30421140)
23. Goode EL, Dunning AM, Kuschel B, et al: Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 62:3052-3057, 2002 (Pubitemid 34602394)
24. Moller P, Borg A, Evans DG, et al: Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 101:555-559, 2002
25. Robson ME, Chappuis PO, Satagopan J, et al: A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17, 2004
26. Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al: Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17:391-400, 2006 (Pubitemid 43329574)
27. Musolino A, Bella MA, Bortesi B, et al: BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study. Breast 16:280-292, 2007 (Pubitemid 46796852)
28. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al: Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43:867-876, 2007 (Pubitemid 46366688)
29. Kriege M, Seynaeve C, Meijers-Heijboer H, et al: Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res Treat 111:303-311, 2008
30. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123, 2007 (Pubitemid 47057729)
31. Bonadona V, Dussart-Moser S, Voirin N, et al: Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat 101:233-245, 2007 (Pubitemid 46115430)
32. Budroni M, Cesaraccio R, Coviello V, et al: Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. BMC Cancer 9:62, 2009
33. John EM, Hopper JL, Beck JC, et al: The Breast Cancer Family Registry: An infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6:R375-R389, 2004
34. Chang ET, Milne RL, Phillips KA, et al: Family history and cancer survival for non-BRCA1/BRCA2-associated breast cancers in the Breast Cancer Family Registry. Breast Cancer Res Treat 117:167-176, 2009
35. Knight JA, Sutherland HJ, Glendon G, et al: Characteristics associated with participation at various stages at the Ontario site of the cooperative family registry for breast cancer studies. Ann Epidemiol 12:27-33, 2002 (Pubitemid 34003069)
36. Andrulis IL, Anton-Culver H, Beck J, et al: Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat 20:65-73, 2002 (Pubitemid 34747718)
37. Neuhausen SL, Ozcelik H, Southey MC, et al: BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: An open resource for collaborative research. Breast Cancer Res Treat 116:379-386, 2009
38. Dite GS, Jenkins MA, Southey MC, et al: Familial risks, early-onset breast cancer, BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 95:448-457, 2003 (Pubitemid 36432419)
39. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 25:2127-2132, 2007 (Pubitemid 46972801)
40. Newman WG, Hadfield KD, Latif A, et al: Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 14:5913-5918, 2008
41. Mote PA, Leary JA, Avery KA, et al: Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer 39:236-248, 2004 (Pubitemid 38209584)